We have been home to many life science start-ups
Project "Treatment of Thromboembolic Pulmonary Hypertension Using JAK Inhibitors" by the Almazov National Medical Research Center, Saint Petersburg - Participant CoLaborator Russia
The project develops a groundbreaking new treatment for thromboembolic pulmonary hypertension using JAK inhibitors, currently applied in cancer therapy. The authors have designed a qualitative model of thromboembolic pulmonary hypertension which allows for efficient selection of the most viable molecules at early stages and maximize the chance of success for the molecules in clinical trials, thus actively implementing the approach from translational medicine.
Altay Therapeutics - Tenant CoLaborator San Francisco
Altay Therapeutics develops next-generation small molecules that treat chronic inflammatory diseases. Altay’s drug development approach identifies new transcription factor targets and enables discovery of their inhibitors. Our team is composed of leaders in small molecule drug development and experts in transcriptional regulation and inflammation. Our first cytostatic drug is a candidate to treat inflammatory diseases, such as fibrosis and ulcerative colitis. We are also developing first-in-class transcriptional inhibitors for oncology indications that include, colon, prostate, liver cancers. Altay is headquartered in San Francisco Mission bay with global collaborators.
BioGraph 55 - Tenant CoLaborator San Francisco
BioGraph 55 is an immuno-oncology target discovery and drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. We leverage a proprietary spatial ‘omics’ platform called SPARTA to capture unique biological information that reflects clinical disease and is druggable. BioGraph 55 is discovering and developing therapies that target the underlying cellular interactomes that give rise to suppressive functional programs in tumors.
Biome Makers - Tenant CoLaborator West Sacramento
Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. We use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products. Biome Makers is committed to the environment and the future of our planet through the management of a sustainable agriculture that allows adequate yields and promises worldwide food security. The first application of the technology is WineSeq, a microbiome based solution that helps to improve vineyard management providing an individualized diagnosis of vineyard health status and value.
Cairn Biosciences - Tenant CoLaborator San Francisco
Cairn Biosciences is developing next-generation therapeutics that address significant challenges in the treatment of serious diseases. Cairn’s drug discovery engine addresses the profound unmet need for new tools to decipher cellular complexity and enable scalable discovery of groundbreaking therapies. Our proprietary approach enables us to monitor multiple dynamic facets of previously inaccessible biology in live cells and fast-track the discovery of a pipeline of drugs for a wide range of indications with an initial focus on cancer.
Coagulant Therapeutics - Tenant CoLaborator San Francisco
Coagulant Therapeutics seeks to address acute bleeding, a significant area of unmet medical need and includes the indications post partum hemorrhage, intracranial hemorrhage, traumatic brain injury and blunt trauma. Translating Coagulation Factors into unique therapeutics. Using 100+ years of collective experience and, as a spin out from Bayer AG, builds on over 30 patents from Bayer and Maxygen, Coagulant Therapeutics has developed an optimized and proprietary rFVIIa molecule, termed CT-001, for the safe and effective pharmaceutical intervention for the treatment of acute bleeding.
CRISPR Therapeutics - Tenant CoLaborator San Francisco
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
DNALite Therapeutics - Tenant CoLaborator San Francisco
DNALite Therapeutics is delivering gene therapies to treat diseases of epithelial tissues. Our first drug is for an orphan disease, Familial Adenomatous Polyposis, that results in a 100% chance of colorectal cancer by the age of 39 which results in patients having their entire colon and rectum removed in their teens. DNALite is replacing these surgeries using gene therapy via our proprietary technology that allows us to deliver biologics to the cells that drive colon cancer. We aim to create first-in-class gene therapy drugs for diseases of the intestinal, respiratory and cervical linings that will treat them at the source rather than addressing only the symptoms.
Epigeneron, Inc. - Tenant CoLaborator Kobe
Epigeneron is a bio-venture launched from Osaka University and the first tenant at CoLaborator Kobe. This company strives to develop practical technologies for drug discovery target identification, and therapies for intractable diseases such as cancer and central nervous system diseases caused by abnormal gene expression.
Eternygen - Tenant CoLaborator Berlin
Eternygen is a Berlin based start-up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen´s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen´s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity.
Explora BioLabs - Tenant CoLaborator San Francisco
Explora BioLabs, an AAALAC-accredited preclinical CRO, provides full-service pharmacology housing and procedure facilities, as well as technical support services, to Bayer and to the CoLaborator’s biotech tenants and neighbors. Explora operates additional pharmacology facilities in South San Francisco and San Diego, and also performs contract research in the areas of oncology, wound healing, metabolic diseases, pharmacokinetics, and toxicology.
Feral GmbH - Tenant CoLaborator Berlin
Feral is a Berlin based biotech start-up, using science and technology to make natural contraception effective and convenient. Our vision is enable women to make informed decisions about their fertility, sexuality and general female health by provide simple and smart solutions. Our first product is a hand held device that uses biochemical and optical sensor for daily hormone monitoring and transmits data wirelessly to a connected app.
Hacarus – Tenant CoLaborator Kobe
Hacarus Inc., founded 2014 in Kyoto, is a leading provider of explainable lightweight AI solutions. Its proprietary AI engine is built using sparse modeling, an emerging technology in data analysis that enables efficient extraction of key features from given data, regardless of their size. This allows expeditious construction of AI algorithms even from small amount of training data while addressing the “black box” problem invariably associated with conventional deep learning. Its applications include medical diagnostics and treatment decision support, and beyond that, potentially a wide range of subjects in life science, such as regenerative medicine. To learn more, visit hacarus.com
INVICOL - Tenant CoLaborator Berlin
INVICOL GmbH, headquartered in Berlin-Wedding, is a young start-up founded in January 2016. We are active in the field of molecular diagnostics of peripheral blood and other body fluids. Circulating blood and body fluids transport therapy-relevant biomarkers and other metabolic products, which need to be identified and analysed. The data obtained are of great value in the field of personalized medicine. Currently INVICOL is focused on detecting free nucleic acids and subcellular compartments such as exosomes. These new approaches to nucleic acid-based diagnostics will become increasingly important in human medicine. The screening can be extended, for example, to include the identification of rare cells from body fluids. INVICOL also has expertise in the field of immuno-screening, i.e. the identification of clinically relevant antibodies and antigens.
Liquid Genomics - Tenant CoLaborator Berlin
Liquid Genomics, Inc. was founded in 2013 in Torrance, California, USA. Liquid Genomics’ CEO is Kathleen Danenberg. The company is focused on transitioning cancer diagnostics from tissue to non-invasive blood-based tests for cancer drug targets. Cancer is a dynamic disease that cannot be effectively treated using a static test. Real time monitoring of drug targets is essential to making informed treatment decisions and adjustments to a patient’s therapy while there is still time to treat. Liquid biopsies allow the physician to continually attack the ever-evolving tumor over the course of the disease with the most effective chemotherapies. Liquid Genomics provides this testing in a rapid, cost-effective manner during clinical trials and beyond.
Mantra Bio - Tenant CoLaborator San Francisco
Mantra Bio is a biotechnology company focused on developing effective and safe exosome-based therapeutics to combat intractable diseases. Mantra Bio is the creator of REVEAL, the world’s first exosome intelligence platform leveraging deep data and lab automation to discover novel drugs.
Myoridge Co. Ltd. - Tenant CoLaborator Kobe
Myoridge is a bio-venture from Kyoto University. Myoridge endeavors to support the solution of challenges in new drug development by providing drug discovery support tools that lower cost through the use of iPS cell-derived cardiomyocytes based on a protein-free method of inducing myocardial differentiation.
NMI TT Pharmaservices - Tenant CoLaborator Berlin
NMI TT Pharmaservices is a Contract Research Organization dedicated to provide integrated experts services to the pharmaceutical industry, as well as to biotechnical and medical technology companies. Our business is focused on high quality products and services and R&D support in the fields of preclinical drug discovery and profiling as well as in safety pharmacology. We are committed to quality, accuracy and efficiency. A distinct customer liaison and support by our project managers ensures a close interaction with our clients to accelerate our customer´s project development.
At our new site at the CoLaborator we will install a novel proprietary technology that will help to bring our expertise to partners in pharma and biotech. Multiplexed protein expression and analysis of cellular signal transduction pathways is performed on a highly reliable Western-Blot like assay system to support drug discovery and biomarker screening. NMI TT, founded in 2002, is a spin-off of the Natural and Medical Sciences Institute (NMI) at the University of Tübingen.
Pantherna Therapeutics GmbH- Tenant CoLaborator Berlin
Pantherna Therapeutics is a privately held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.
ProLynx LLC - Tenant CoLaborator San Francisco
ProLynx LLC, founded in 2009, is developing a technology platform that overcomes major limitations of releasable linkers currently used in drug conjugation. The technology uses sets of novel linkers that cleave at different, pre-programmed rates to allow the controlled, predictable and sustained release of native, active drugs – peptides, proteins and small molecules – from circulating and fixed macromolecular conjugates.
Provitro - Tenant CoLaborator Berlin and Kobe
Provitro AG is an innovative molecular-pathological service provider for preclinical and clinical research in pharmacology and biotechnology. The company's principal business area is based on a well-stocked tissue bank and close scientific cooperation with pathologists of Charité University Hospital Berlin. Normal and diseased tissue samples can be provided as single slide or customized Tissue Microarray block for biomarker analyzes. Its competence is not limited to target validation by means of immunohistochemistry and In-situ-hybridization but includes, as well, the development of protocols for both manual and automated IHC and ISH staining. Pathological result evaluation completes this field of service. Furthermore, normal and diseased tissue samples can be provided as single slides or customized tissue microarrays for in-house biomarker analyzes.
Tacalyx GmbH- Tenant CoLaborator Berlin
Tacalyx, located with its laboratories in Berlin and Potsdam, is focusing on the development of novel treatments for cancer. Targets are cancer-specific carbohydrates that are not only very specific for especially aggressive cancers but that also contribute significantly to virulence and metastasis of these malignant tumors. The unique approach of Tacalyx is based on the ability to synthesize virtually any carbohydrate structure as target for antibodies These will be converted into powerful drugs and developed for demonstration of Proof-of-Concept (PoC) in clinical studies.
Project "Development of Aldosterone Synthase Inhibitor – First-Ever Agent in Treatment of Cardiometabolic Diseases" by Target Medicals - Participant CoLaborator Russia
The main focus of the project is the search of new regulation mechanisms of the renin–angiotensin–aldosterone system (RAAS) through the development of viable selective aldosterone synthase inhibitor. Solving this problem will allow to apply new approaches in the treatment of chronic kidney and heart failure. The agent the authors are developing is one of a kind and has every chance to become the first in its class.
Treamid Therapeutics - Tenant CoLaborator Berlin
Treamid Therapeutics develops innovative treatments in areas of high unmet medical needs. Our portfolio includes potential new treatments for several endocrine and respiratory diseases. Both areas threaten health gains made during the past century and are one of the most important levers for improving health care in the 21st century. Treamid Therapeutics is a Berlin based start-up founded in 2017 by serial life sciences entrepreneurs.
Project "CAR-NK Cells As Platform for Universal Cancer Therapy" by the Institute of Molecular and Cellular Biology, Siberian Branch of the RAS, Novosibirsk - Participant CoLaborator Russia
The project focuses on the development of one of the most promising approaches in cancer therapy: chimeric antigen receptor (CAR) cell-based therapy. The products existing on the market are based on autologous (taken from the patient) cells, which drastically complicates the procedure. Besides, current field of application of CAR therapy is limited to oncohematology, while in solid tumors this therapy is a lot less efficient. The project suggests that the use of modified allogenic CAR-NK cells instead of autologous CAR-T cells will solve the problem of high cost, while further modifications will allow to increase their efficiency for a wider range of cancerous diseases.
Xcell Biosciences - Tenant CoLaborator San Francisco
Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Our proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune cell therapies.